Skip to main content

Table 1 Baseline characteristics of the 1003 AS patients and 1747 RA patients who were working at baseline

From: Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients

Parameter

AS

n

RA

n

Age (years), mean (SD)

40.7 (10.6)

1003

47.3 (9.9)

1747

Female, %

36.7

1003

72.4

1747

Disease duration (years), mean (SD)

7.3 (7.8)

979

7.9 (7.6)

1654

Disease activity

0–10 Likert, mean (SD)

6.3 (1.7)

1000

–

 

0–100 mm VAS, mean (SD)

–

 

59.1 (18.0)

1724

CRP (mg/dL), median (min, max)

1.0 (0.0, 42.7)

906

0.9 (0.0, 20.0)

1534

Fatigue

0–10 cm VAS, mean (SD)

5.6 (2.4)

997

–

 

0–100 mm VAS, mean (SD)

–

 

57.4 (24.9)

1735

Pain

0–10 Likert, mean (SD)

6.3 (2.2)

990

–

 

0–100 mm VAS, mean (SD)

–

 

61.6 (21.4)

1736

Anxiety/depression

(EQ-5D)

No problems, %

53.6

998

52.1

1738

Some problems, %

42.7

44.4

Extreme problems, %

3.7

3.6

WPAI:SHP

% work time missed due to AS/RAa

No timed missed

61.9

776

61.3

1293

Some time missed

38.1

38.7

% impairment while working due to AS/RAb, mean (SD)

48.3 (26.9)

889

49.5 (27.1)

1530

% overall work impairment due to AS/RAc, mean (SD)

52.9 (29.8)

716

54.1 (29.0)

1171

% activity impairment due to AS/RAd, mean (SD)

53.4 (24.6)

990

54.0 (24.9)

1718

  1. aAbsenteeism
  2. bPresenteeism
  3. cWork productivity loss
  4. dActivity impairment
  5. AS, ankylosing spondylitis; CRP, C-reactive protein; EQ-5D, European Quality of Life 5 Dimensions; RA, rheumatoid arthritis; SD, standard deviation; VAS, visual analogue scale; WPAI:SHP, Work Productivity and Activity Impairment—Special Health Problems